Hydroxyurea versus misonidazole with radiation in cervical carcinoma: Long-term follow-up of a gynecologic oncology group trial

Frederick B. Stehman, Brian N. Bundy, Gillian Thomas, Henry M. Keys, Gerrit D'Ablaing, Wesley C. Fowler, Rodrigue Mortel, William T. Creasman

Research output: Contribution to journalArticle

94 Scopus citations

Abstract

Purpose: Long-term follow-up data of a randomized trial that compared hydroxyurea and the hypoxic-cell radiosensitizer to misonidazole as adjuncts to standard radiation therapy in locally advanced carcinoma of the cervix are reported. Patients and Methods: Three hundred eight women were entered, and all 294 eligible patients are assessable as randomized. Eighty-one percent of patients have been monitored for 5 years or to death. Results: There was an advantage for hydroxyurea in progression-free interval and survival (P = .05 and P = .066, respectively). There was no significant difference in the distribution of sites of failure between the regimens. For the 39% of patients with stages III to IVA disease, the advantage in progression-free interval for hydroxyurea was significant (47.8% v 33.6%). More leukopenia occurred on the hydroxyurea regimen than on the misonidazole regimen. Conclusion: In summary, these data provide stronger evidence than our previous analysis that hydroxyurea is superior to misonidazole as an adjunct to radiation therapy. For patients with locally advanced carcinoma of the cervix, hydroxyurea continues to be the adjunct of choice with radiation.

Original languageEnglish (US)
Pages (from-to)1523-1528
Number of pages6
JournalJournal of Clinical Oncology
Volume11
Issue number8
DOIs
StatePublished - Jan 1 1993
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Hydroxyurea versus misonidazole with radiation in cervical carcinoma: Long-term follow-up of a gynecologic oncology group trial'. Together they form a unique fingerprint.

  • Cite this